supplementary material

[키워드] 1080 24 hour 24 hours 48 hour 48 hours ACE2 ADEs administration Adverse adverse event adverse events AEs ALEA All participant All participants allergy alveolar angiotensin angiotensin converting enzyme angiotensin converting enzyme 2 anticipated attending physician bind Blinding block randomization Blood bovine breath buffer calcium cells cellular cholesterol Chronic kidney disease class clinical Clinical improvement clinical trial clinical trials Cohort Combination comparator Compliance Concentration conducted Consent contraindication contributing to Control control arm controls COVID-19 COVID-19 adult patient COVID-19 patients current cytokine Data collection Data monitoring committee death declined defined delivery described Device dialysis discretion dissemination dose drug Effect Efficacy EGFR element Eligible participants end point End-Expiratory Pressure Endotracheal intubation enrolled Enrollment enrolment epithelial Escalation EudraCT evaluate exclusion exclusion criteria expected fatty Fatty acid feasibility free fatty acid Frequency hospital hospitalised hypoxia impair include inclusion criteria index Inflammatory marker inflammatory markers Inflammatory response intensive care intensive care unit Intervention investigator Kidney disease lack liver liver failure Local lung lung lavage mechanical ventilation mechanical ventilator mechanically ventilated patient mechanically ventilated patients mixture Mortality nebulisation number objective Open-label opinion Ordinal Scale other treatment outcome oxidative stress Oxygenation PaO participant Patient PCR PEEP Phosphatidylcholine phosphatidylethanolamine phosphatidylglycerol phosphatidylinositol phospholipid PIP Placebo plasma Pneumothorax Positive end-expiratory pressure Prevent Primary outcome progression Protein protocol pulmonary compliance pulmonary hemorrhage pulmonary ventilation quantification randomisation randomised randomised controlled trial Randomized Randomized controlled trial reached receive recorded recruitment reduction Registered reported Respiratory failure SAEs Sample size SARS-CoV-2 viral load SARS-CoV-2 virus secondary outcome Secondary outcomes Serious Adverse Events severe COVID-19 severity sphingomyelin Stage Standard Standard of care status Study protocol subject supplementary material surface tension surfactant synthesis tension the WHO tissue damage total sample size tracheal tracheal aspirate Tracheal aspirates transfer Treatment Trial Trial Steering Committee turnover unique university University College London usual standard of care Ventilation Ventilation Index ventilatory support VFD vibrating mesh nebulizer Viral Viral load virus water website weight with COVID-19 worsening
[DOI] 10.1186/s13063-020-04944-5 PMC 바로가기 [Article Type] Randomized Controlled Trial